EPGN-2154

N/A

Report date: 2026/02/06 20:01:23
NME

Base Information

Drug NameEPGN-2154
Drug Alias NameEPGN2154EPGN-2154
ClassificationSmall molecules
Mechanisms of ActionLysophosphatidic acid receptor Edg-2 antagonists
TargetsLysophosphatidic acid receptor Edg-2
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEpigen Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesChildren's Hospital Los AngelesEpigen Biosciences Inc
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A